Core Viewpoint - The company is initiating a plan to issue H-shares and list on the Hong Kong Stock Exchange, driven by a significant divergence in revenue growth between its domestic and international businesses, with international operations becoming the main growth engine while domestic operations face challenges [3][4]. Group 1: Financial Performance - In 2024, the company's international business revenue grew by 47.33% to 2.55 billion yuan, accounting for over 60% of total revenue, while domestic revenue declined by 10.28% [2][4]. - For the first half of 2025, the company reported total revenue of 2.04 billion yuan, a year-on-year increase of 2.57%, with net profit attributable to shareholders rising by 4.30% to 161 million yuan [4]. - The company's revenue from domestic operations in the first half of 2025 was 818 million yuan, down 1.63%, while international revenue was 1.22 billion yuan, up 5.58% [4]. Group 2: Strategic Initiatives - The company aims to deepen its global strategy and enhance its capital strength through the issuance of H-shares, which is seen as a pragmatic response to the sluggish growth in the domestic market [3][4]. - The company is also seeking investment or divestment opportunities for its subsidiary BFPC, which has been operating at a loss, to improve overall profitability and market competitiveness [9]. Group 3: Business Model and Market Position - The company operates in the CDMO (Contract Development and Manufacturing Organization) sector, providing a full range of services from product development to marketing support [8]. - Since its listing in 2019, the company has shown a trend of increasing revenue from 1.58 billion yuan to 4.21 billion yuan by 2024, with a notable shift in the revenue contribution from domestic to international markets [8].

Core Viewpoint - Xianle Health plans to issue H-shares and seek investment opportunities for its subsidiary BFPC to enhance its global strategy and capital strength [1][2] Group 1: Company Overview - Xianle Health, established in 1993 and listed on the Shenzhen Stock Exchange in 2019, specializes in contract R&D and manufacturing for the nutrition and health food industry, offering comprehensive solutions including research, development, manufacturing, packaging, logistics, and marketing support [2] - The company has been pursuing a global strategy since 2012, establishing operations in the U.S. and acquiring Sirio Germany in 2016 to enhance its localized production capabilities [2][3] Group 2: Subsidiary Performance - BFPC, a leading U.S. CDMO for nutritional supplements, has not contributed positively to Xianle Health's financial performance, reporting losses of 143 million, 151 million, and 86.94 million yuan from 2023 to the first half of 2025 [3] - As of June 30, 2025, the goodwill from the acquisition of BFPC stands at 251 million yuan, with a total goodwill value of 435 million yuan, representing 17.05% of the company's equity [4] Group 3: Financial Performance - In 2024, Xianle Health reported revenues of 4.211 billion yuan, a year-on-year increase of 17.56%, with net profit of 325 million yuan, up 15.66% [5] - Domestic sales declined by 10.28% to 1.661 billion yuan, while international sales grew by 47.33% to 2.550 billion yuan [5] - For the first half of 2025, revenues reached 2.042 billion yuan, a 2.57% increase, with net profit of 161 million yuan, up 4.30% [5] Group 4: Market Dynamics - The domestic market is facing challenges due to generational shifts and rapid innovation, while the supply side is undergoing structural changes, leading to increased pressure on traditional brands [5][6] - The industry is entering a phase of accelerated innovation characterized by diverse product categories and rapid iterations, necessitating higher responsiveness and innovation capabilities from contract manufacturers [6]

豪威集团表示，此次港股上市是公司向高质量发展、链接全球的重要里程碑。豪威集团总经理高文宝在 上市仪式上表示，依托"A+H"双资本平台，公司将持续完善全球化战略布局，坚持技术创新，携手全球 伙伴与人才，以科技赋能无限，共创智能可持续的未来。 中证报中证网讯（记者 乔翔）2026年1月12日，豪威集团在香港联合交易所主板挂牌上市，成为国内 CIS领域首家实现"A+H"上市的企业。 作为一家全球化Fabless（无晶圆厂模式）半导体设计公司，CMOS图像传感器（CIS）是豪威集团主要 产品。豪威集团主要从事三大业务线，包括图像传感器解决方案、显示解决方案以及模拟解决方案，能 够提供多样化的图像传感器、显示产品、模拟IC和其他半导体组件组合。 本次全球发售共计4580万股H股，最终发行价敲定每股104.80港元，募资总额约48亿港元（绿鞋前）， 由瑞银、中金公司、中国平安资本、广发证券担任联席保荐人，募集资金将用于研发投入、全球市场渗 透等方向，也将进一步支撑公司在高增长赛道的拓展与全球化布局。 ...

Core Viewpoint - The company, OmniVision Technologies, officially listed on the Hong Kong Stock Exchange, becoming the first "A+H" enterprise of the year and the first stock in the image sensor sector in Hong Kong [1] Group 1: Listing and Financials - OmniVision's H-shares rose over 15% on the first trading day, closing at HKD 120.7 per share [1] - The global offering consisted of 45.8 million H-shares, with a final issue price set at HKD 104.80 per share, raising approximately HKD 4.8 billion (before the green shoe option) [1] - The funds raised will be allocated towards R&D investments and global market penetration, supporting the company's expansion in high-growth sectors [1] Group 2: Business Overview - OmniVision is a global fabless semiconductor design company, primarily focusing on CMOS image sensors (CIS) [2] - The company operates in three main business lines: image sensor solutions, display solutions, and analog solutions, providing a diverse range of products [2] - According to Frost & Sullivan, OmniVision ranks as the third-largest digital image sensor supplier globally, with a market share of 13.7% as of 2024 [2] Group 3: Product Applications and Innovations - OmniVision's products are widely used in smartphones, automotive, medical, security, and emerging markets such as machine vision and smart glasses [2] - The company is actively engaging in AI and emerging markets, enhancing high-end CIS product performance for smartphones and maintaining its leading position in automotive CIS [2] - The company has developed its own LCOS technology, which is integrated into automotive smart cockpit applications and AR-HUD systems, contributing to high-precision virtual image projection [3] Group 4: Financial Performance - For the first three quarters of 2025, OmniVision reported revenue of CNY 21.783 billion, a year-on-year increase of 15.20%, and a net profit attributable to shareholders of CNY 3.210 billion, up 35.15% [3] - In Q3, the company achieved revenue of CNY 7.827 billion, a 14.81% increase year-on-year, with a net profit of CNY 1.182 billion, growing 17.26% [3] - The growth in performance is attributed to the company's rapid penetration in the automotive smart driving sector and significant expansion in the smart imaging terminal market [3]

新京报贝壳财经讯 1月11日，仙乐健康发布公告称，公司已于2026年1月8日召开第四届董事会第十七次 会议，会议审议通过了拟发行H股股票并在香港联合交易所有限公司主板上市的相关议案。公告指出， 此举旨在深化全球化战略布局，利用国际资本市场优势，提高公司资本实力和综合竞争力，加快海外业 务发展，完善境内外双循环格局，巩固行业地位。目前，公司正就发行及上市事宜与相关中介机构展开 商讨，具体细节尚未最终确定。 ...

仙乐健康（300791）(300791.SZ)发布公告，为深化公司全球化战略布局，利用国际资本市场优势，打 造多元化资本运作平台，进一步提高公司资本实力和综合竞争力，以加快海外业务发展，完善境内外双 循环格局，巩固行业地位，公司拟发行境外上市外资股(H股)股票并申请在香港联交所主板挂牌上市。 ...

Group 1 - The core viewpoint of the article is that Xianle Health (300791.SZ) plans to issue overseas listed foreign shares (H-shares) and apply for listing on the main board of the Hong Kong Stock Exchange to enhance its global strategy and capital strength [1] Group 2 - The company aims to leverage the advantages of international capital markets to create a diversified capital operation platform [1] - The initiative is intended to accelerate the development of overseas business and improve the domestic and international dual circulation pattern [1] - This move is expected to strengthen the company's competitive position within the industry [1]

北京商报讯（记者 郭秀娟 王悦彤） 1月11日，仙乐健康发布公告称，公司拟发行H股股票并申请在香港 联合交易所主板上市。此举旨在深化公司全球化战略布局，利用国际资本市场优势，提升资本实力和综 合竞争力，加快海外业务发展，完善境内外双循环格局。 ...

Core Viewpoint - The company plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and capital strength [1] Group 1 - The fourth meeting of the fourth board of directors is scheduled for January 8, 2026, to review the proposal for issuing H-shares [1] - The initiative aims to leverage international capital market advantages to improve the company's capital strength and overall competitiveness [1] - The company is currently in discussions with relevant intermediaries regarding the issuance and listing details, which are not yet finalized [1]

Core Viewpoint - Linglong Tire (601966) emphasizes the importance of communication with the capital market and aims to enhance market confidence through various channels of interaction with shareholders [1] Group 1: Communication Strategy - The company maintains open communication with shareholders through multiple channels, including the Shanghai Stock Exchange E-interaction platform, investor hotlines, online earnings briefings, investor reception days, company research, brokerage strategy meetings, and institutional roadshows [1] - The company is committed to ensuring transparency in information disclosure while actively conveying the progress of its operational plans and long-term investment value [1] Group 2: Strategic Focus - Linglong Tire will continue to prioritize technological innovation as the core driving force behind its operations [1] - The company aims to advance its globalization strategy alongside the development of retail channels and supporting systems [1] - By leveraging multi-dimensional strategic synergies, the company seeks to strengthen its fundamentals and enhance its core competitiveness [1] Group 3: Long-term Goals - The company is focused on solidifying its foundation to achieve its established medium- to long-term strategic objectives [1]